LifeSan, the clinical research arm of Centaur is located in Centaur House, conforms to international regulatory standards. LifeSan is fully integrated, offering end-to-end clinical research solutions from Bioequivalence and Bioavailability (BA-BE) studies to drug interaction studies to phase II, III and IV clinical trials. LifeSan caters to global leaders and leading Indian companies. LifeSan is successfully inspected by the USFDA, MHRA (UK), MCC and BfArM (Germany). LifeSan would soon be foraying into the area of pharmacovigilance. LifeSan offers world class facilities with state of the art machinery, 42 beds, a separate ICU section and is manned by 6 doctors and a well-trained and experienced staff.

LifeSan has successfully co-developed a globally patented new chemical entity (NCE) DPOCL for the treatment of Diabetic Foot Ulcer, an unmet medical need. Centaur collaborated with CytoTools AG, Germany and successfully completed Phase II and III trials in India. India has the highest number of diabetics globally, and a large population in the pre-diabetes stage, which makes this segment attractive. The marketing approval is awaited from the drug authorities, on receipt of which DPOCL will be introduced by Centaur, for the first time in the world, in India.